<DOC>
	<DOCNO>NCT00919009</DOCNO>
	<brief_summary>Most HCC patient diagnose advanced stage Korea , transcatheter arterial chemoembolization consider key modality palliative treatment HCC patient . TACE currently one mainstay palliative treatment worldwide patient inoperable HCC show survival benefit patient unresectable HCC . TACE consist primarily directly target chemotherapy embolization artery feed tumor , inevitably result hypoxic insult HCC surround liver tissue . Ischemic injury TACE find induce upregulation circulate vascular endothelial growth factor ( VEGF ) , essential tumor growth , invasion metastasis patient HCC . Recent study show significant correlation pre-TACE level circulate VEGF VEGF upregulation TACE HCC characteristic , include tumor size , vascular invasion , metastasis . TACE consist primarily directly target chemotherapy embolization artery feed tumor , inevitably result hypoxic insult HCC surround liver tissue . Central tumor hypoxia find upregulate proangiogenic growth factor , potent mediator tumor angiogenesis . Therefore , expression circulate tissue VEGF enhance TACE patient animal HCC , could probability adverse effect TACE HCC patient . In addition , investigator demonstrate transient increment serum VEGF level TACE significantly correlate poor outcome tumor progression , especially outcomes relevant distant metastasis . Therefore , finding suggest rationale apply adjuvant therapy anti-angiogenesis agent additional treatment anti-angiogenesis TACE TACE select group patient HCC . The aim study evaluate efficacy safety sorafenib 400 mg bid TACE patient unresectable and/or inoperable HCC .</brief_summary>
	<brief_title>Combination Transcatheter Arterial Chemoembolization ( TACE ) Sorafenib Patients With Unresectable Hepatocellular Carcinoma ( HCC )</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<criteria>Patients must provide sign write informed consent Patients clinical histological diagnosis HCC base guideline Korean Liver Cancer Study Group National Cancer Center Korea Patients least one , bidimensionally measurable lesion multiphasic spiral CT scan dynamic contrastenhanced MRI Patients stage III IVa HCC accord modify International Union Against Cancer TNM stag criterion without invasion main portal vein , inferior vena cava extrahepatic metastasis size large tumor 10cm study entry Patients unresectable inoperable HCC indicate TACE treatment choice accord guideline Korean Liver Cancer Study Group National Cancer Center Korea Age ≥ 20 year ECOG Performance Status 0 or1 ChildPugh class A B ( ChildPugh score 7 ) Life expectancy least 16 week Adequate bone marrow , liver renal function assess follow laboratory requirement conduct within 7 day prior screen : Hb ≧ 9g/dl Absolute neutrophil count &gt; 1000/mm3 Platelet count ≧ 60x109/L Adequate clot function : INR &lt; 1.5 Hepatic : AST ALT &lt; 5 X ULN Renal : serum creatinine &lt; 1.5 x ULN Bilirubin ≦ 3mg/dL Patients diffuse infiltrative type HCC poorly define Presence hepatic encephalopathy intractable ascites Active clinically serious infection ( &gt; grade 2 NCICTC version 3.0 ) , include spontaneous bacterial peritonitis History esophageal gastric variceal bleed Patients liver transplant list History cardiac disease : congestive heart failure &gt; NYHA class 2 ; active coronary artery disease ( myocardial infarction 6 month prior study entry allow ) , cardiac arrythmias require antiarrythmic therapy uncontrolled hypertension diabetes mellitis History AIDS/HIV infection Patients seizure disorder require medication ( steroids anti epileptic ) History organ allograft Patients evidence history bleed diathesis Patients undergoing renal dialysis Previous concurrent cancer distinct primary site histology cancer evaluate study except cervical carcinoma situ , treat basal cell carcinoma , superficial bladder tumor ( Ta , Tis &amp; T1 ) cancer curatively treat &gt; 3 year prior study entry .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>TACE</keyword>
	<keyword>Sorafenib</keyword>
</DOC>